Related Experiment Video
Updated: May 5, 2026
09:14
High efficiency, Site-specific Transfection of Adherent Cells with siRNA Using Microelectrode Arrays MEA
Published on: September 13, 2012
12.7K
Delivery of RNAi-Based Oligonucleotides by Electropermeabilization
Sophie Chabot1, Sandrine Pelofy, Justin Teissié
1Centre National de la Recherche Scientifique (CNRS), Institut de Pharmacologie et de Biologie Structurale (IPBS) BP 64182, 205 route de Narbonne, Toulouse F-31077, France. Muriel.Golzio@ipbs.fr.
Pharmaceuticals (Basel, Switzerland)
|November 27, 2013
Summary
Electropermeabilization (EP) enhances the delivery of RNA interference (RNAi) oligonucleotides for cancer therapeutics by temporarily opening cell membranes. This method overcomes biological barriers for effective gene silencing.
Area of Science:
- Molecular Biology
- Biotechnology
- Cancer Therapeutics
Background:
- RNA interference (RNAi) offers potent gene silencing for cancer therapy.
- Efficient delivery of RNAi oligonucleotides into target cells remains a significant challenge.
- Electropermeabilization (EP) is a physical method for enhancing cellular uptake.
Purpose of the Study:
- To review therapeutic RNAi oligonucleotides suitable for electrotransfer.
- To elucidate the mechanisms of RNAi oligonucleotide electrotransfer.
- To outline technical settings for preclinical electrotransfer applications.
Main Methods:
- Review of existing literature on RNAi and electropermeabilization.
- Analysis of mechanisms underlying EP-mediated delivery of oligonucleotides.
- Compilation of technical parameters for preclinical electrotransfer.
Main Results:
- EP facilitates the transient permeabilization of cell membranes.
- This permeabilization allows efficient in vitro and in vivo cytoplasmic delivery of RNAi oligonucleotides.
- Various therapeutic RNAi oligonucleotides are amenable to electrotransfer.
Conclusions:
- Electropermeabilization is a promising technique for delivering RNAi-based therapeutics.
- Understanding EP mechanisms and optimizing technical settings are crucial for preclinical development.
- EP holds potential for overcoming delivery barriers in RNAi cancer therapeutics.
